Amandeep Singh, MD
Psychiatry · Jackson, MSNPI 1497197859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 37.9% of the total. 2025 is the largest year on record at $991, 5.1 times the $196 reported in 2019.
Across 156 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Axsome Therapeutics, Inc.$292
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$263
- Lundbeck LLC$187
- Teva Pharmaceuticals USA, Inc.$154
- Takeda Pharmaceuticals U.S.A., Inc.$144
- plus $765 from 9 others
What the payments were for
- Food & beverage$2,88099%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,103 |
| Axsome Therapeutics, Inc. | 7 | $292 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $263 |
| Lundbeck LLC | 7 | $187 |
| Teva Pharmaceuticals USA, Inc. | 7 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $144 |
| Neurocrine Biosciences, Inc. | 5 | $144 |
| Johnson & Johnson | 7 | $138 |
| Vanda Pharmaceuticals Inc. | 6 | $135 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Pfizer | 3 | $55 |
| Alkermes, Inc. | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Corium, LLC | 1 | $14 |
How this compares
$2,908 in reported general payments places this provider in the 80th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 49 | $401,121 |
| AustedoDeutetrabenazine | 44 | $209,256 |
| VraylarCariprazine Hcl | 77 | $121,647 |
| Invega SustennaPaliperidone Palmitate | 35 | $65,285 |
| FanaptIloperidone | 21 | $60,943 |
| TrintellixVortioxetine Hydrobromide | 27 | $16,929 |
| Aripiprazole | 93 | $7,885 |
| Bupropion XlBupropion Hcl | 312 | $5,625 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 57 | $5,034 |
| Oxcarbazepine | 79 | $4,676 |
| Quetiapine Fumarate | 283 | $4,428 |
| Duloxetine Hcl | 253 | $3,787 |
| Paliperidone ErPaliperidone | 24 | $3,624 |
| Clozapine | 34 | $3,438 |
| Hydroxyzine Pamoate | 292 | $2,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $144 | $401,12149 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $154 | $209,25644 claims |
| AbbVieVraylar | $1,103 | $121,64777 claims |
| Johnson & JohnsonInvega Sustenna | $138 | $65,28535 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $135 | $60,94321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $144 | $16,92927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Jackson
- Jon JacksonJackson$834K
- John NortonJackson$173K
- Krishan GuptaJackson$26K
- Kristen BevillJackson$12K
- Mark ResterJackson$9K
- Roy ReevesJackson$8K
- Andrew BishopJackson$6K
- Hunter McLendonJackson$5K
- Douglas ByrdJackson$5K
- Marshall BelagaJackson$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.